300318 博晖创新
午间休市 11-18 11:30:00
资讯
新帖
简况
博晖创新:公司研发活动严格按照《科技伦理审查办法(试行)》规定
证券之星 · 11-13
博晖创新:公司研发活动严格按照《科技伦理审查办法(试行)》规定
博晖创新(300318)2026年三季报简析:亏损收窄
证券之星 · 10-31
博晖创新(300318)2026年三季报简析:亏损收窄
股市必读:博晖创新三季报 - 第三季度单季净利润同比增长39.55%
证券之星 · 10-30
股市必读:博晖创新三季报 - 第三季度单季净利润同比增长39.55%
博晖创新(300318)9月30日股东户数3.03万户,较上期增加3.7%
证券之星 · 10-29
博晖创新(300318)9月30日股东户数3.03万户,较上期增加3.7%
图解博晖创新三季报:第三季度单季净利润同比增长39.55%
证券之星 · 10-29
图解博晖创新三季报:第三季度单季净利润同比增长39.55%
博晖创新(300318)10月26日主力资金净买入161.30万元
证券之星 · 10-26
博晖创新(300318)10月26日主力资金净买入161.30万元
博晖创新最新公告:获得结核分枝杆菌检测试剂盒医疗器械注册证
证券之星 · 10-12
博晖创新最新公告:获得结核分枝杆菌检测试剂盒医疗器械注册证
博晖创新:云南博晖已具备人血白蛋白生产条件
证券之星 · 09-15
博晖创新:云南博晖已具备人血白蛋白生产条件
股市必读:博晖创新新发布《关于曲靖血液制品生产基地进展的公告》
证券之星 · 08-31
股市必读:博晖创新新发布《关于曲靖血液制品生产基地进展的公告》
股市必读:博晖创新新发布《2026年半年度报告摘要》
证券之星 · 08-27
股市必读:博晖创新新发布《2026年半年度报告摘要》
博晖创新(300318)披露2026年半年度报告,8月25日股价上涨3.7%
证券之星 · 08-25
博晖创新(300318)披露2026年半年度报告,8月25日股价上涨3.7%
博晖创新(300318.SZ)发布上半年业绩,归母净亏损1560.66万元
智通财经 · 08-25
博晖创新(300318.SZ)发布上半年业绩,归母净亏损1560.66万元
图解博晖创新中报:第二季度单季净利润同比增长43.14%
证券之星 · 08-25
图解博晖创新中报:第二季度单季净利润同比增长43.14%
博晖创新(300318)6月30日股东户数2.93万户,较上期减少8.46%
证券之星 · 08-25
博晖创新(300318)6月30日股东户数2.93万户,较上期减少8.46%
股市必读:博晖创新(300318)8月17日董秘有最新回复
证券之星 · 08-18
股市必读:博晖创新(300318)8月17日董秘有最新回复
公司问答丨博晖创新:公司实现了小型台式质谱仪的国内生产 并推向科研用户市场
格隆汇 · 08-17
公司问答丨博晖创新:公司实现了小型台式质谱仪的国内生产 并推向科研用户市场
博晖创新:分子诊断和免疫诊断优势互补
证券之星 · 08-17
博晖创新:分子诊断和免疫诊断优势互补
博晖创新:相关的核心零部件也均已完全实现国产化
证券之星 · 08-17
博晖创新:相关的核心零部件也均已完全实现国产化
博晖创新:层析工艺静丙已有中长期研发规划
证券之星 · 08-17
博晖创新:层析工艺静丙已有中长期研发规划
博晖创新:人用狂犬病疫苗采用原代地鼠肾细胞培养
证券之星 · 08-17
博晖创新:人用狂犬病疫苗采用原代地鼠肾细胞培养
加载更多
公司概况
公司名称:
北京博晖创新生物技术集团股份有限公司
所属行业:
专用设备制造业
上市日期:
2012-05-23
主营业务:
北京博晖创新生物技术集团股份有限公司的主营业务是体外诊断产品的研发、生产与销售。公司的主要产品是检验仪器、检测试剂。
发行价格:
15.00
{"stockData":{"symbol":"300318","market":"SZ","secType":"STK","nameCN":"博晖创新","latestPrice":4.3,"timestamp":1794974418000,"preClose":4.35,"halted":0,"volume":2519300,"delay":0,"changeRate":-0.0115,"floatShares":799000000,"shares":817000000,"eps":-0.1016,"marketStatus":"午间休市","change":-0.05,"latestTime":"11-18 11:30:00","open":4.38,"high":4.4,"low":4.28,"amount":10876700,"amplitude":0.0276,"askPrice":4.3,"askSize":110,"bidPrice":4.29,"bidSize":935,"shortable":0,"etf":0,"ttmEps":-0.1016,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794978000000},"marketStatusCode":3,"adr":0,"adjPreClose":4.35,"symbolType":"stock","openAndCloseTimeList":[[1794965400000,1794972600000],[1794978000000,1794985200000]],"highLimit":4.79,"lowLimit":3.91,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":816900495,"isCdr":false,"pbRate":2.81,"roa":"--","roe":"--","epsLYR":-0.1125,"committee":0.195767,"marketValue":3513000000,"turnoverRate":0.0032,"status":1,"floatMarketCap":3434000000},"requestUrl":"/m/hq/s/300318","defaultTab":"news","newsList":[{"id":"2683578289","title":"博晖创新:公司研发活动严格按照《科技伦理审查办法(试行)》规定","url":"https://stock-news.laohu8.com/highlight/detail?id=2683578289","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683578289?lang=zh_cn&edition=full","pubTime":"2026-11-13 16:24","pubTimestamp":1794558250,"startTime":"0","endTime":"0","summary":"证券之星消息,博晖创新11月13日在投资者关系平台上答复投资者关心的问题。关注到公司主营诊断用制剂、诊断治疗设备。临床研究的伦理审查现由内部、合作医院还是外部机构承担?公司研发活动严格按照《科技伦理审查办法(试行)》规定,相关临床研究均委托专业的临床机构进行,并按照相关规定经委托机构伦理审查程序批准后实施。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111300028428.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","BK0028","BK0048","300318"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679226892","title":"博晖创新(300318)2026年三季报简析:亏损收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=2679226892","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679226892?lang=zh_cn&edition=full","pubTime":"2026-10-31 07:50","pubTimestamp":1793404259,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期博晖创新发布2026年三季报。根据财报显示,博晖创新亏损收窄。其中,毛利率32.67%,同比减16.94%,净利率-7.6%,同比增22.21%,销售费用、管理费用、财务费用总计2.06亿元,三费占营收比32.92%,同比增1.49%,每股净资产1.55元,同比减6.12%,每股经营性现金流-0.09元,同比增32.56%,每股收益-0.03元,同比增26.52%证券之星价投圈财报分析工具显示:业务评价:去年的净利率为-20.86%,算上全部成本后,公司产品或服务的附加值不高。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103100017242.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0251","BK0048","300318"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679623097","title":"股市必读:博晖创新三季报 - 第三季度单季净利润同比增长39.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679623097","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679623097?lang=zh_cn&edition=full","pubTime":"2026-10-30 06:26","pubTimestamp":1793312801,"startTime":"0","endTime":"0","summary":"业绩披露要点:2026年三季报显示归母净利润为-2462.99万元,同比上升26.73%;第三季度扣非净利润为-1036.37万元,同比下降1295.4%。公司公告汇总:董事会审议通过向关联方君正科技增加借款额度不超过5亿元,合计借款总额度不超过15亿元;拟续聘大华会计师事务所为2026年度审计机构,审计费用170万元,与上期持平。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000010268.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300318"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679058794","title":"博晖创新(300318)9月30日股东户数3.03万户,较上期增加3.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679058794","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679058794?lang=zh_cn&edition=full","pubTime":"2026-10-29 19:12","pubTimestamp":1793272350,"startTime":"0","endTime":"0","summary":"证券之星消息,近日博晖创新披露,截至2026年9月30日公司股东户数为3.03万户,较6月30日增加1084.0户,增幅为3.7%。在生物制品行业个股中,博晖创新股东户数低于行业平均水平,截至9月30日,生物制品行业平均股东户数为3.6万户。从股价来看,2026年6月30日至2026年9月30日,博晖创新区间涨幅为25.12%,在此期间股东户数增加1084.0户,增幅为3.7%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102900046304.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0048","BK0028","300318","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679614418","title":"图解博晖创新三季报:第三季度单季净利润同比增长39.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679614418","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679614418?lang=zh_cn&edition=full","pubTime":"2026-10-29 01:58","pubTimestamp":1793210326,"startTime":"0","endTime":"0","summary":"证券之星消息,博晖创新2026年三季报显示,前三季度公司主营收入6.26亿元,同比下降0.42%;归母净利润-2462.99万元,同比上升26.73%;扣非净利润-2518.36万元,同比下降34.46%;其中2026年第三季度,公司单季度主营收入2.31亿元,同比上升2.58%;单季度归母净利润-902.32万元,同比上升39.55%;单季度扣非净利润-1036.37万元,同比下降1295.4%;负债率51.97%,投资收益-37.19万元,财务费用3214.78万元,毛利率32.67%。财报数据概要请见下图:本文数据来源于博晖创新2026年三季报,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102900003410.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300318"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678115766","title":"博晖创新(300318)10月26日主力资金净买入161.30万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2678115766","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678115766?lang=zh_cn&edition=full","pubTime":"2026-10-26 15:32","pubTimestamp":1792999971,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年10月26日收盘,博晖创新报收于4.8元,上涨2.56%,换手率0.91%,成交量7.3万手,成交额3468.63万元。10月26日的资金流向数据方面,主力资金净流入161.3万元,占总成交额4.65%,游资资金净流出100.27万元,占总成交额2.89%,散户资金净流出61.03万元,占总成交额1.76%。博晖创新主营业务:体外诊断产品的研发、生产与销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102600015025.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","BK0028","BK0048","300318"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674873027","title":"博晖创新最新公告:获得结核分枝杆菌检测试剂盒医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2674873027","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674873027?lang=zh_cn&edition=full","pubTime":"2026-10-12 17:21","pubTimestamp":1791796900,"startTime":"0","endTime":"0","summary":"博晖创新(300318.SZ)公告称,公司近日获得国家药品监督管理局颁发的医疗器械注册证,产品为结核分枝杆菌复合群及利福平、异烟肼耐药基因突变检测试剂盒(芯片杂交法),注册分类为Ⅲ类,有效期至2031年10月8日。该产品用于体外定性检测人痰液样本中结核分枝杆菌复合群核酸及相关耐药基因突变。此次注册证的取得丰富了公司产品种类,有利于提升核心竞争力和市场拓展能力,但实际销售情况受市场推广等因素影响存在不确定性。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200022821.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09996","BK1574","159883","BK0028","BK1100","BK1583","BK0048","300318","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667504692","title":"博晖创新:云南博晖已具备人血白蛋白生产条件","url":"https://stock-news.laohu8.com/highlight/detail?id=2667504692","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667504692?lang=zh_cn&edition=full","pubTime":"2026-09-15 08:51","pubTimestamp":1789433468,"startTime":"0","endTime":"0","summary":"2、公司控股孙公司云南博晖已经获批静注人免疫球蛋白《药品补充申请批准通知书》,目前正在等待云南省药监局颁发《药品GMP符合性检查告知书》及《药品生产许可证》,待完成后,云南博晖将具备静注人免疫球蛋白生产条件。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091500006713.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0048","300318","BK0028","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663025551","title":"股市必读:博晖创新新发布《关于曲靖血液制品生产基地进展的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2663025551","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663025551?lang=zh_cn&edition=full","pubTime":"2026-08-31 09:22","pubTimestamp":1788139363,"startTime":"0","endTime":"0","summary":"公司公告汇总关于曲靖血液制品生产基地进展的公告北京博晖创新生物技术集团股份有限公司控股孙公司博晖生物制药(云南)有限公司投资13.8亿元建设曲靖血液制品生产基地,已完成人血白蛋白的上市许可持有人及生产场地变更,并取得国家药监局和云南省药监局的相关批准证书,具备人血白蛋白生产条件。河北博晖2025年人血白蛋白销售收入约15994.36万元,占公司全年收入19.40%。云南博晖将于近日正式投产,并持续推进其他品种的产业化生产。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100003673.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0048","BK0251","300318"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662747037","title":"股市必读:博晖创新新发布《2026年半年度报告摘要》","url":"https://stock-news.laohu8.com/highlight/detail?id=2662747037","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662747037?lang=zh_cn&edition=full","pubTime":"2026-08-27 05:49","pubTimestamp":1787780952,"startTime":"0","endTime":"0","summary":"公司公告汇总:2026年半年度报告摘要显示,归母净利润为-15,606,630.04元,同比上升16.49%;经营活动现金流量净额为-36,650,410.85元,同比改善27.59%。第九届董事会第二次会议决议公告北京博晖创新生物技术集团股份有限公司于2026年8月25日召开第九届董事会第二次会议,审议通过《2026年半年度报告》及其摘要。非经营性资金占用及其他关联资金往来情况汇总表截至2026年6月末,公司与控股股东、实际控制人及其附属企业之间无非经营性资金占用。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700010490.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0048","300318","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662758456","title":"博晖创新(300318)披露2026年半年度报告,8月25日股价上涨3.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662758456","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662758456?lang=zh_cn&edition=full","pubTime":"2026-08-25 22:14","pubTimestamp":1787667263,"startTime":"0","endTime":"0","summary":"截至2026年8月25日收盘,博晖创新报收于5.05元,较前一交易日上涨3.7%,最新总市值为41.25亿元。该股当日开盘4.84元,最高5.07元,最低4.81元,成交额达8112.01万元,换手率为2.03%。近日,博晖创新披露《2026年半年度报告》。本报告期末总资产为4,390,580,020.84元,较上年度末的4,304,243,808.48元增长2.01%;归属于上市公司股东的净资产为1,271,761,949.08元,较上年度末的1,285,185,304.19元下降1.04%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500050429.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","BK0048","300318","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662947739","title":"博晖创新(300318.SZ)发布上半年业绩,归母净亏损1560.66万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662947739","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662947739?lang=zh_cn&edition=full","pubTime":"2026-08-25 19:14","pubTimestamp":1787656484,"startTime":"0","endTime":"0","summary":"智通财经APP讯,博晖创新 发布2026年半年度报告,报告期内,公司实现营业收入3.96亿元,同比下降2.09%。归属于上市公司股东净亏损1560.66万元,归属于上市公司股东的扣除非经常性损益净亏损1481.99万元。报告期内,公司体外诊断主要销售产品为人体微量元素检测及HPV检测,终端用户为医院和第三方检测机构。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1485245.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0251","BK0028","300318","BK0048"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662717733","title":"图解博晖创新中报:第二季度单季净利润同比增长43.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662717733","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662717733?lang=zh_cn&edition=full","pubTime":"2026-08-25 18:16","pubTimestamp":1787653016,"startTime":"0","endTime":"0","summary":"证券之星消息,博晖创新2026年中报显示,上半年度公司主营收入3.96亿元,同比下降2.09%;归母净利润-1560.66万元,同比上升16.49%;扣非净利润-1481.99万元,同比上升24.38%;其中2026年第二季度,公司单季度主营收入2.06亿元,同比上升1.66%;单季度归母净利润-832.14万元,同比上升43.14%;单季度扣非净利润-799.06万元,同比上升45.48%;负债率51.06%,投资收益-69.13万元,财务费用1918.81万元,毛利率32.78%。财报数据概要请见下图:本文数据来源于博晖创新2026年中报,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500038780.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300318"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662738239","title":"博晖创新(300318)6月30日股东户数2.93万户,较上期减少8.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662738239","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662738239?lang=zh_cn&edition=full","pubTime":"2026-08-25 17:52","pubTimestamp":1787651561,"startTime":"0","endTime":"0","summary":"证券之星消息,近日博晖创新披露,截至2026年6月30日公司股东户数为2.93万户,较3月31日减少2706.0户,减幅为8.46%。在生物制品行业个股中,博晖创新股东户数低于行业平均水平,截至6月30日,生物制品行业平均股东户数为3.55万户。从股价来看,2026年3月31日至2026年6月30日,博晖创新区间跌幅为28.55%,在此期间股东户数减少2706.0户,减幅为8.46%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500037640.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","BK0028","BK0048","300318"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660431528","title":"股市必读:博晖创新(300318)8月17日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2660431528","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660431528?lang=zh_cn&edition=full","pubTime":"2026-08-18 01:34","pubTimestamp":1786988099,"startTime":"0","endTime":"0","summary":"截至2026年8月17日收盘,博晖创新报收于5.11元,下跌0.97%,换手率1.13%,成交量8.97万手,成交额4572.09万元。董秘最新回复投资者: 公司的微流控芯片及检测分析仪器均为自研。当日关注点交易信息汇总:8月17日主力资金净流出380.87万元,占总成交额8.33%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081800001868.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0251","300318","BK0048"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660486453","title":"公司问答丨博晖创新:公司实现了小型台式质谱仪的国内生产 并推向科研用户市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2660486453","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660486453?lang=zh_cn&edition=full","pubTime":"2026-08-17 17:39","pubTimestamp":1786959555,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["300318","BK0028","BK0048","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660483461","title":"博晖创新:分子诊断和免疫诊断优势互补","url":"https://stock-news.laohu8.com/highlight/detail?id=2660483461","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660483461?lang=zh_cn&edition=full","pubTime":"2026-08-17 16:30","pubTimestamp":1786955430,"startTime":"0","endTime":"0","summary":"证券之星消息,博晖创新08月17日在投资者关系平台上答复投资者关心的问题。公司当前拥有的技术平台主要包括分子诊断、免疫诊断、原子吸收和质谱。分子诊断和免疫诊断主要进行病原体检测,分子诊断具有更高的灵敏度和特异性,免疫诊断具有时间短、操作方便等优点,两个诊断平台优势互补,面向不同的使用场景。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081700020609.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","BK0028","BK0048","300318"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660483405","title":"博晖创新:相关的核心零部件也均已完全实现国产化","url":"https://stock-news.laohu8.com/highlight/detail?id=2660483405","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660483405?lang=zh_cn&edition=full","pubTime":"2026-08-17 16:30","pubTimestamp":1786955430,"startTime":"0","endTime":"0","summary":"证券之星消息,博晖创新(300318)08月17日在投资者关系平台上答复投资者关心的问题。投资者提问:公司的微流控芯片及检测分析仪器均为自研。请问核心芯片设计与制造、配套仪器的核心零部件,是否已完全实现国产化?有无卡脖子风险?博晖创新回复:尊敬的投资者,您好!目前,公司基于微流控技术相关产品的设计和加工制造均在国内实现,相关的核心零部件也均已完全实现国产化,目前无卡脖子风险。感谢您的关注!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081700020607.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0048","BK0028","BK0251","300318"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660836714","title":"博晖创新:层析工艺静丙已有中长期研发规划","url":"https://stock-news.laohu8.com/highlight/detail?id=2660836714","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660836714?lang=zh_cn&edition=full","pubTime":"2026-08-17 16:27","pubTimestamp":1786955240,"startTime":"0","endTime":"0","summary":"证券之星消息,博晖创新(300318)08月17日在投资者关系平台上答复投资者关心的问题。投资者提问:血液制品板块的技术升级:公司正推动云南血制基地投产。在血液制品领域,是否有布局新一代技术(如层析法静丙、重组人白蛋白等)的规划?博晖创新回复:尊敬的投资者,您好!公司持续关注行业前沿技术发展方向,在新一代技术布局方面,层析工艺静丙已有中长期研发规划,并按计划推进。感谢您的关注!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081700020520.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300318","BK0048","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660839134","title":"博晖创新:人用狂犬病疫苗采用原代地鼠肾细胞培养","url":"https://stock-news.laohu8.com/highlight/detail?id=2660839134","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660839134?lang=zh_cn&edition=full","pubTime":"2026-08-17 16:27","pubTimestamp":1786955235,"startTime":"0","endTime":"0","summary":"证券之星消息,博晖创新08月17日在投资者关系平台上答复投资者关心的问题。谢谢博晖创新回复:尊敬的投资者,您好!博晖生物制药股份有限公司主要从事疫苗产品的研发、生产和销售,目前已上市销售的产品人用狂犬病疫苗采用原代地鼠肾细胞培养,无致瘤风险;生产工艺成熟,不含佐剂与硫柳汞,安全性良好;接种后起效迅速且保护持久。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081700020510.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0251","159646","BK0048","300318"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1794974444938,"stockEarnings":[{"period":"1week","weight":-0.0247},{"period":"1month","weight":-0.1068},{"period":"3month","weight":-0.123},{"period":"6month","weight":-0.142},{"period":"1year","weight":-0.4563},{"period":"ytd","weight":-0.3062}],"compareEarnings":[{"period":"1week","weight":-0.0216},{"period":"1month","weight":-0.0354},{"period":"3month","weight":-0.0796},{"period":"6month","weight":-0.1208},{"period":"1year","weight":-0.0975},{"period":"ytd","weight":-0.0968}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京博晖创新生物技术集团股份有限公司","boardCode":"AI0035","boardName":"专用设备制造业","stockholders":"30345人(较上一季度增加3.70%)","perCapita":"26315股","listingDate":"2012-05-23","address":"北京市昌平区生命园路9号院","registeredCapital":"81690万元","survey":" 北京博晖创新生物技术集团股份有限公司的主营业务是体外诊断产品的研发、生产与销售。公司的主要产品是检验仪器、检测试剂。","listedPrice":15},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.54.0","shortVersion":"4.54.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"博晖创新(300318)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供博晖创新(300318)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"博晖创新,300318,博晖创新股票,博晖创新股票老虎,博晖创新股票老虎国际,博晖创新行情,博晖创新股票行情,博晖创新股价,博晖创新股市,博晖创新股票价格,博晖创新股票交易,博晖创新股票购买,博晖创新股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"博晖创新(300318)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供博晖创新(300318)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}